Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.
Ziad Bakouny(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), José Manuel Ruiz Morales(Hospital Médica Sur), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Praful Ravi(Dana-Farber Cancer Institute), Connor Wells(Queen Mary University of London), Ajjai Alva(Michigan Medicine), John A. Steinharter(Memorial Sloan Kettering Cancer Center), Julia Shapiro(Cabrini Hospital), Frede Donskov(Aarhus University Hospital), Ian D. Davis(Austin Health), Wanling Xie(Dana-Farber Cancer Institute), Lori Wood(Dalhousie University), Christian Kollmannsberger(BC Cancer Agency), Shaan Dudani(William Osler Health System), Francis Parnis(Centre for Cancer Biology), Neeraj Agarwal(University of Utah), Chun Loo Gan(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Anil Kapoor(People’s University)
Cited by 20
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k